Purple Biotech Ltd
PPBT
$2.53
-$0.12-4.53%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -68.37% | -- | 63.33% | -- | |
| Gross Profit | 68.37% | -- | -63.33% | -- | |
| SG&A Expenses | -40.17% | -39.51% | -45.67% | -28.34% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -83.79% | -36.59% | -3.08% | 13.11% | |
| Operating Income | 83.79% | 36.59% | 3.08% | -13.11% | |
| Income Before Tax | 91.46% | 53.20% | 19.59% | -4.25% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 91.46% | 53.20% | 19.59% | -4.25% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -83.87% | -54.55% | -3.13% | -24.00% | |
| Net Income | 91.51% | 53.19% | 19.68% | -4.39% | |
| EBIT | 83.79% | 36.59% | 3.08% | -13.11% | |
| EBITDA | 83.89% | 36.89% | 2.50% | -13.17% | |
| EPS Basic | 94.65% | 64.49% | 42.81% | -17,175.28% | |
| Normalized Basic EPS | 94.87% | 67.11% | 41.21% | -- | |
| EPS Diluted | 94.71% | 64.49% | 42.20% | -17,175.28% | |
| Normalized Diluted EPS | 94.87% | 67.11% | 41.21% | -- | |
| Average Basic Shares Outstanding | 59.08% | 31.07% | 40.24% | -99.40% | |
| Average Diluted Shares Outstanding | 59.08% | 31.07% | 40.24% | -99.40% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |